Buy, Sell or Hold: Omnix Biopharmaceuticals (OMRI-Q)

Omnix Biopharmaceuticals (OMRI-Q)

0.00

0.00 (0.00%) 1d

PAST TOP PICK

(A Top Pick Nov 20/06. Up 30%.) Missed a quarter and there were competitive threats so he got out and missed the upswing.

TOP PICK

Using plasma to stop bleeding in the surgical applications. 200% growth. Sells at about 20 X earnings. Management owns a big chunk. Just reported stellar numbers. Will ultimately get taken over.

Showing 1 to 2 of 2 entries

Omnix Biopharmaceuticals(OMRI-Q) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Omnix Biopharmaceuticals is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Omnix Biopharmaceuticals(OMRI-Q) Frequently Asked Questions

What is Omnix Biopharmaceuticals stock symbol?

Omnix Biopharmaceuticals is a OTC stock, trading under the symbol OMRI-Q on the (). It is usually referred to as or OMRI-Q

Is Omnix Biopharmaceuticals a buy or a sell?

In the last year, there was no coverage of Omnix Biopharmaceuticals published on Stockchase.

Is Omnix Biopharmaceuticals a good investment or a top pick?

Omnix Biopharmaceuticals was recommended as a Top Pick by on . Read the latest stock experts ratings for Omnix Biopharmaceuticals.

Why is Omnix Biopharmaceuticals stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Omnix Biopharmaceuticals worth watching?

In the last year 0 stock analysts on Stockchase covered Omnix Biopharmaceuticals. The stock is worth watching.

What is Omnix Biopharmaceuticals stock price?

On , Omnix Biopharmaceuticals (OMRI-Q) stock closed at a price of $.

Most Recent Experts

Stockchase Insights

5i Research

Michael Hakes - CFA, MBA

Murray Wealth Group

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Cerity Partners

Brenda Vingiello, CIO, Sand Hill Global Advisors

Sand Hill Global Advisors

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.